307 results on '"Akerley W"'
Search Results
2. OA22.05 TTFields and Immune-Checkpoint Inhibitor in Metastatic Non-Small Cell Lung Cancer: PD-L1 Subgroups in the Phase 3 LUNAR Study
3. 1723P CLEC3B mRNA expression levels are linked to distinct genetic backgrounds, transcriptomic signatures and survival in NSCLC
4. P24.01 Turnaround Time and Variant Prevalence of a Blood-based KRAS Test in Patients With NSCLC
5. P47.07 KEAPSAKE Study of Telaglenastat vs Placebo Plus Standard-of-Care in 1L KEAP1/NRF2-Mutated Non-Squamous Metastatic NSCLC
6. P27.01 Patterns of Care and Outcomes in Clinical T3N0M0 Non-Small Cell Lung Cancer Without Invasion of Other Structures
7. P63.11 Real-World Survival Outcomes of Patients with Limited Stage Small Cell Lung Cancer (LS-SCLC) by Choice of Platinum Chemotherapy
8. 1030TiP An open-label multicenter phase Ib study of AN0025, a selective inhibitor of the prostaglandin E2 receptor-type-4 receptor, in combination with pembrolizumab in patients with advanced solid tumors
9. 1418P Impact of TTFields therapy on global and functional health-related quality of life (HRQoL) in metastatic non-small cell lung cancer (mNSCLC) from the pivotal LUNAR study
10. 1335P Phase Ib study to evaluate the safety and tolerability of osimertinib with ipilimumab in EGFRm NSCLC
11. P01.07 Real World Outcomes of Advanced Non-Small Cell Lung Cancer (NSCLC) With Attention to Carboplatin Area Under the Curve (AUC) = 5 Versus 6
12. P89.05 Management of Patients with EGFR and ALK-Mutated Advanced Non-Small Cell Lung Cancer Post-TKI Therapy – A Real-World Survival Analysis
13. FP05.01 Real-World Survival Outcomes of Patients with Malignant Pleural Mesothelioma by Choice of Second-line Therapy
14. FP07.17 The Impact of Blood Based Host Immune Profile to Identify Aggressive Early Stage NSCLC
15. OA09.05 Real-World Survival Outcomes of Patients with Malignant Pleural Mesothelioma by Physician’s Choice of First-line Platinum Chemotherapy
16. MA08.03 Immunotherapy Alone or with Chemotherapy in Advanced NSCLC? Utility of Clinical Factors and Blood-Based Host Immune Profiling.
17. P15.02 Phase Ib Study to Evaluate the Safety and Efficacy of Osimertinib in Combination with Ipilimumab in EGFR Mutated NSCLC
18. Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure
19. MA14.09 Real-World Survival of Relapsed Compared to De-Novo Stage IV Diagnosis of Advanced Non-Small Cell Lung Cancer
20. Safety, tolerability and activity of autologous T-cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer: A phase Ib/IIa randomised pilot study
21. P1.01-35 Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers
22. Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity
23. Real-world Performance of Blood-Based Proteomic Profiling in Frontline Immunotherapy Treatment in Advanced stage NSCLC
24. OA12.06 Mutational Landscape of BRAF V600E Positive Lung Cancer Patients Following BRAF Directed Therapy Failure
25. MA03.10 Population-Based Relative Risks for Lung Cancer Based on Complete Family History of Lung Cancer
26. P3.01-13 Prognosis of Non-driver, Never Smoker Metastatic Non-Small Lung Cancer (NSCLC)
27. Phase Ib KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients
28. OA02.02 Long Term Follow up of Ipilimumab and Targeted Therapy for Metastatic EGFR/ALK Lung Cancer
29. P2.03-058 Tiger-3: A Phase 3 Randomized Study of Rociletinib Vs Chemotherapy in EGFR-mutated Non-small Cell Lung Cancer (NSCLC)
30. Sequential Versus Concurrent Chemoradiotherapy for Post-Operative pN2-N3 Non–Small Cell Lung Cancer
31. 1590TiP - Safety, tolerability and activity of autologous T-cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer: A phase Ib/IIa randomised pilot study
32. PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers
33. LBA40 - Phase Ib KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients
34. Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology
35. Efficacy Analysis for Molecular Subgroups in MARQUEE: a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial of Tivantinib (ARQ 197) Plus Erlotinib versus Placebo plus Erlotinib in Previously Treated Patients with Locally Advanced or Metastatic, Non-squamous, Non-small Cell Lung Cancer (NSCLC)
36. A Unique Geographical Analysis of Lung Cancer Patients in the State of Utah
37. A single-arm phase II trial evaluating docetaxel, vinorelbine, and GM-CSF in stage IV melanoma.
38. Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
39. Final report: Combination of MPC-6827 with temozolomide for the treatment of patients with metastatic melanoma.
40. Bevacizumab/erlotinib (BEER) as first-line treatment for untreated, advanced non-squamous non-small cell lung cancer (NSNSCLC).
41. A clinical study investigating MPC-6827 with carboplatin in the treatment of patients with relapsed glioblastoma multiforme.
42. Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancer
43. Safety of Bevacizumab Therapy in Subjects with Brain Metastases due to Non–Small-Cell Lung Cancer (NSCLC)
44. Two phase 1 studies of MPC-6827, a novel vascular disrupting agent (VDA), in patients with advanced solid tumors and CNS metastases
45. A randomized phase 2 trial of combretatstatin A4 phosphate (CA4P) in combination with paclitaxel and carboplatin to evaluate safety and efficacy in subjects with advanced imageable malignancies
46. Cancer survival: Which low molecular weight heparin (LMWH) is best?
47. Erlotinib as first-line treatment for untreated advance stage NSCLC with good prognosis
48. PD-063 Kinetic model of survival for advanced non-small cell lungcancer (NSCLC) predicts enrichment-bias affects 2nd Line treatment trials
49. P-442 Erlotinib for good prognosis patients with untreated, advanced stage NSCLC
50. Natual history of non-small cell lung cancer in non-smokers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.